Hematologic complications of cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
1996
|
| Schriftenreihe: | Hematology, oncology clinics of North America
10,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | X S., S. 293 - 535 Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV010735090 | ||
| 003 | DE-604 | ||
| 005 | 20150203 | ||
| 007 | t| | ||
| 008 | 960430s1996 xx ad|| |||| 00||| eng d | ||
| 035 | |a (OCoLC)34561634 | ||
| 035 | |a (DE-599)BVBBV010735090 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 |a DE-12 |a DE-29 | ||
| 050 | 0 | |a RC633 | |
| 084 | |a YC 1700 |0 (DE-625)153192: |2 rvk | ||
| 084 | |a YC 2200 |0 (DE-625)153198:13352 |2 rvk | ||
| 245 | 1 | 0 | |a Hematologic complications of cancer |c Stephen D. Nimer ... guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 1996 | |
| 300 | |a X S., S. 293 - 535 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Hematology, oncology clinics of North America |v 10,2 | |
| 650 | 7 | |a Bloed |2 gtt | |
| 650 | 7 | |a Bloedvorming |2 gtt | |
| 650 | 7 | |a Complicaties |2 gtt | |
| 650 | 2 | |a Hémopathies - étiologie | |
| 650 | 7 | |a Therapieën |2 gtt | |
| 650 | 2 | |a Tumeurs - complications | |
| 650 | 7 | |a Tumoren |2 gtt | |
| 650 | 4 | |a Blood |x Diseases | |
| 650 | 4 | |a Hematologic Diseases |x etiology | |
| 650 | 4 | |a Neoplasms |x complications | |
| 650 | 4 | |a Tumors | |
| 650 | 0 | 7 | |a Hämoblastose |0 (DE-588)4130932-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Koagulopathie |0 (DE-588)4007276-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immunsuppression |0 (DE-588)4026641-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Tumoranämie |0 (DE-588)4126563-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Blutkrankheit |0 (DE-588)4007281-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Granulozytopenie |0 (DE-588)4211999-6 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Blutkrankheit |0 (DE-588)4007281-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Koagulopathie |0 (DE-588)4007276-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Tumoranämie |0 (DE-588)4126563-4 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 3 | 1 | |a Immunsuppression |0 (DE-588)4026641-2 |D s |
| 689 | 3 | 2 | |a Granulozytopenie |0 (DE-588)4211999-6 |D s |
| 689 | 3 | |5 DE-604 | |
| 689 | 4 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 4 | 1 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |D s |
| 689 | 4 | 2 | |a Hämoblastose |0 (DE-588)4130932-7 |D s |
| 689 | 4 | |5 DE-604 | |
| 700 | 1 | |a Nimer, Stephen D. |e Sonstige |4 oth | |
| 830 | 0 | |a Hematology, oncology clinics of North America |v 10,2 |w (DE-604)BV000625446 |9 10,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007167241&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-007167241 | |
Datensatz im Suchindex
| _version_ | 1823607493737054208 |
|---|---|
| adam_text |
HEMATOLOGIC COMPLICATIONS OF CANCER
i
!
CONTENTS
Preface xi
Stephen D. Nimer and David W. Golde
Therapy Related Myeloid Leukemia 293
Michael J. Thirman and Richard A. Larson
One of the most serious possible consequences of cancer therapy
is the development of a second cancer, especially leukemia. Sev¬
eral distinct subsets of therapy related leukemia can be distin¬
guished currently. These include classic therapy related myeloid
leukemia, leukemia that follows treatment with agents that inhibit
topoisomerase II, acute lymphoblastic leukemia, and leukemias
with 21q22 rearrangements or inv(16) or t(15;17). These types of
leukemia are discussed in detail in this article.
Bone Marrow Metastases 321
Elizabeth J. Shpall, Adrian P. Gee, Christopher Hogan,
Pablo Cagnoni, Ursula Gehling, Lisa Hami, Wilbur Franklin,
Scott I. Bearman, Maureen Ross, and Roy B. Jones
This article discusses the clinical significance of bone marrow
metastases and the current methods being used to detect tumor
cells in marrow. The strategies being investigated for eradicating
cancer cells from marrow in patients receiving hematopoietic cell
autografts also are reviewed.
Anemia of Cancer 345
Alison R. Moliterno and Jerry L. Spivak
Cancer patients frequently develop anemia, due either to the
cancer itself or to the effects of cancer related therapy. Recent
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA
VOLUME 10 • NUMBER 2 • APRIL 1996 vii
years have brought insights into both the pathogenesis of the
anemia of cancer and the extent to which erythropoietin regula¬
tion participates in this process. Although transfusion therapy
was the mainstay of therapy for symptomatic anemia in the
past, clinical trials have demonstrated that recombinant human
erythropoietin can alleviate both anemia and transfusion require¬
ments in many cancer patients and may prove to have an im¬
portant role in the treatment of cancer related anemia in the fu¬
ture.
Hemolytic Disorders Associated with Cancer 365
Michael Rytting, Laura Worth, and Norman Jaffe
Three principal environmental causes of hemolytic anemia in
malignancy have been identified: (1) hemolysis mediated by auto
antibodies to red cells; (2) hemolysis due to microangiopathic
disorders; and (3) chemotherapy induced red cell destruction.
These three environmental stressors occur rarely in cancer pa¬
tients, and they form the subject of this review.
Chemotherapy and Neutropenia 377
Seung K. Kim and George D. Demetri
Myelosuppression is the most common toxicity associated with
the administration of dose intensive cytotoxic chemotherapy. The
basic understanding of neutrophil biology and the physiology of
chemotherapy induced neutropenia has advanced tremendously
in the past 2 decades. Concordantly, the ability to reduce the
morbidity associated with neutropenia has improved. Adjunctive
cytokine and progenitor cell support of hematologic recovery
after myelosuppressive therapy have proved to be models of
translational research and have led to novel therapeutic initiatives
for patients with cancer and hematologic malignancies. In this
article, fundamental aspects of neutrophil production are dis¬
cussed, and the clinical development of hematopoietic cytokines
active on cells of the leukocyte lineages is presented.
Transfusion and Stem Cell Support in Cancer Treatment 397
David L. Wuest
Intensification of therapeutic regimens, improved patient sur¬
vival, and advances in cytokine and cellular therapies have led
to increasingly complex requirements for transfusion and stem
cell support in cancer treatment. This article focuses on current
and evolving issues in red blood cell, platelet, and granulocyte
transfusion support, as well as measures to avoid increasingly
important complications of transfusion therapy, such as alloim
munization, graft versus host disease, cytomegalovirus infection,
and immunomodulation. Issues concerning current applications
of hematopoietic stem cell transplantation and future prospects
also are discussed.
viii CONTENTS
The Thrombocytopenia of Cancer: Prospects for Effective
Cytokine Therapy 431
Kenneth Kaushansky
Cancer and its treatment launch many attacks on megakaryocyte
and platelet production. This article focuses on the hematopoietic
cytokines that affect this process. Prior to the cloning of thrombo
poietin, at least two of these cytokines, IL 11 and PIXY 321,
displayed promising clinical effects. To determine how these
agents will compare to the physiologic regulator of platelet pro¬
duction will require carefully controlled clinical trials. The next
few years most certainly will see the resolution of many of the
complications of thrombocytopenia.
Coagulation Disorders in Cancer 457
Kathryn E. Goad and Harvey R. Gralnick
Coagulation disorders are common in cancer patients. This article
reviews the coagulation laboratory findings in these patients and
the thromboembolic and hemorrhagic manifestations of malig¬
nancy. Among the many topics addressed are Trousseau's syn¬
drome, disseminated intravascular coagulation, and acquired von
Willebrand disease. Pathogenesis of the coagulation disorders
and recommendations for treatment of various syndromes are
discussed.
Thrombotic Microangiopathies Associated with Drugs and
Bone Marrow Transplantation 485
Joel L. Moake and John J. Byrnes
This type of thrombotic microangiopathy more commonly resem¬
bles the hemolytic uremic syndrome (HUS) than thrombotic
thrombocytopenic purpura (TTP). The syndrome has been associ¬
ated with the use of cyclosporin, mitomycin C, combinations of
other chemotherapeutic and immunosuppressive agents, and to¬
tal body irradiation. Endothelial cell injury and von Willebrand
factor may be involved in pathogenesis of the intravascular plate¬
let aggregation and tissue (especially renal) ischemia and in¬
farction that characterize the entity. The most effective therapy
for thrombotic microangiopathy associated with drugs and bone
marrow transplantation has not been determined,
Hypercoagulability in Cancer 499
Karen B. Green and Roy L. Silverstein
The association of cancer with a hypercoagulable state is docu¬
mented by numerous clinical, biochemical, pathologic, and phar
macologic studies. This association is manifested clinically by an
increased incidence of intravascular thrombotic events in cancer
patients and by fibrin deposition in and around tumor beds.
Thromboembolic disease is a major cause of morbidity and mor
CONTENTS ix
tality in patients with malignancy. This article discusses the com¬
plex pathogenesis of this problem and the associated laboratory
and clinical syndromes with recommendations on diagnosis and
treatment.
Index 531
Subscription Information Inside back cover
X CONTENTS |
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV010735090 |
| callnumber-first | R - Medicine |
| callnumber-label | RC633 |
| callnumber-raw | RC633 |
| callnumber-search | RC633 |
| callnumber-sort | RC 3633 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | YC 1700 YC 2200 |
| ctrlnum | (OCoLC)34561634 (DE-599)BVBBV010735090 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 cb4500</leader><controlfield tag="001">BV010735090</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150203</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">960430s1996 xx ad|| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)34561634</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010735090</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC633</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 1700</subfield><subfield code="0">(DE-625)153192:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 2200</subfield><subfield code="0">(DE-625)153198:13352</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hematologic complications of cancer</subfield><subfield code="c">Stephen D. Nimer ... guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X S., S. 293 - 535</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">10,2</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bloed</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bloedvorming</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Complicaties</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Hémopathies - étiologie</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapieën</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tumeurs - complications</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumoren</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood</subfield><subfield code="x">Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematologic Diseases</subfield><subfield code="x">etiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">complications</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tumors</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hämoblastose</subfield><subfield code="0">(DE-588)4130932-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Koagulopathie</subfield><subfield code="0">(DE-588)4007276-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunsuppression</subfield><subfield code="0">(DE-588)4026641-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tumoranämie</subfield><subfield code="0">(DE-588)4126563-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Blutkrankheit</subfield><subfield code="0">(DE-588)4007281-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Granulozytopenie</subfield><subfield code="0">(DE-588)4211999-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Blutkrankheit</subfield><subfield code="0">(DE-588)4007281-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Koagulopathie</subfield><subfield code="0">(DE-588)4007276-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Tumoranämie</subfield><subfield code="0">(DE-588)4126563-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Immunsuppression</subfield><subfield code="0">(DE-588)4026641-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="2"><subfield code="a">Granulozytopenie</subfield><subfield code="0">(DE-588)4211999-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="4" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="1"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2="2"><subfield code="a">Hämoblastose</subfield><subfield code="0">(DE-588)4130932-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="4" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nimer, Stephen D.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Hematology, oncology clinics of North America</subfield><subfield code="v">10,2</subfield><subfield code="w">(DE-604)BV000625446</subfield><subfield code="9">10,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007167241&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007167241</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV010735090 |
| illustrated | Illustrated |
| indexdate | 2025-02-09T19:00:29Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007167241 |
| oclc_num | 34561634 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-12 DE-29 |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-12 DE-29 |
| physical | X S., S. 293 - 535 Ill., graph. Darst. |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Saunders |
| record_format | marc |
| series | Hematology, oncology clinics of North America |
| series2 | Hematology, oncology clinics of North America |
| spelling | Hematologic complications of cancer Stephen D. Nimer ... guest ed. Philadelphia [u.a.] Saunders 1996 X S., S. 293 - 535 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Hematology, oncology clinics of North America 10,2 Bloed gtt Bloedvorming gtt Complicaties gtt Hémopathies - étiologie Therapieën gtt Tumeurs - complications Tumoren gtt Blood Diseases Hematologic Diseases etiology Neoplasms complications Tumors Hämoblastose (DE-588)4130932-7 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Koagulopathie (DE-588)4007276-9 gnd rswk-swf Immunsuppression (DE-588)4026641-2 gnd rswk-swf Arzneimittelnebenwirkung (DE-588)4003134-2 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Tumoranämie (DE-588)4126563-4 gnd rswk-swf Blutkrankheit (DE-588)4007281-2 gnd rswk-swf Granulozytopenie (DE-588)4211999-6 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Blutkrankheit (DE-588)4007281-2 s DE-604 Koagulopathie (DE-588)4007276-9 s Tumoranämie (DE-588)4126563-4 s Cytostatikum (DE-588)4068347-3 s Immunsuppression (DE-588)4026641-2 s Granulozytopenie (DE-588)4211999-6 s Arzneimittelnebenwirkung (DE-588)4003134-2 s Hämoblastose (DE-588)4130932-7 s Nimer, Stephen D. Sonstige oth Hematology, oncology clinics of North America 10,2 (DE-604)BV000625446 10,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007167241&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Hematologic complications of cancer Hematology, oncology clinics of North America Bloed gtt Bloedvorming gtt Complicaties gtt Hémopathies - étiologie Therapieën gtt Tumeurs - complications Tumoren gtt Blood Diseases Hematologic Diseases etiology Neoplasms complications Tumors Hämoblastose (DE-588)4130932-7 gnd Cytostatikum (DE-588)4068347-3 gnd Koagulopathie (DE-588)4007276-9 gnd Immunsuppression (DE-588)4026641-2 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd Krebs Medizin (DE-588)4073781-0 gnd Tumoranämie (DE-588)4126563-4 gnd Blutkrankheit (DE-588)4007281-2 gnd Granulozytopenie (DE-588)4211999-6 gnd |
| subject_GND | (DE-588)4130932-7 (DE-588)4068347-3 (DE-588)4007276-9 (DE-588)4026641-2 (DE-588)4003134-2 (DE-588)4073781-0 (DE-588)4126563-4 (DE-588)4007281-2 (DE-588)4211999-6 (DE-588)4143413-4 |
| title | Hematologic complications of cancer |
| title_auth | Hematologic complications of cancer |
| title_exact_search | Hematologic complications of cancer |
| title_full | Hematologic complications of cancer Stephen D. Nimer ... guest ed. |
| title_fullStr | Hematologic complications of cancer Stephen D. Nimer ... guest ed. |
| title_full_unstemmed | Hematologic complications of cancer Stephen D. Nimer ... guest ed. |
| title_short | Hematologic complications of cancer |
| title_sort | hematologic complications of cancer |
| topic | Bloed gtt Bloedvorming gtt Complicaties gtt Hémopathies - étiologie Therapieën gtt Tumeurs - complications Tumoren gtt Blood Diseases Hematologic Diseases etiology Neoplasms complications Tumors Hämoblastose (DE-588)4130932-7 gnd Cytostatikum (DE-588)4068347-3 gnd Koagulopathie (DE-588)4007276-9 gnd Immunsuppression (DE-588)4026641-2 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd Krebs Medizin (DE-588)4073781-0 gnd Tumoranämie (DE-588)4126563-4 gnd Blutkrankheit (DE-588)4007281-2 gnd Granulozytopenie (DE-588)4211999-6 gnd |
| topic_facet | Bloed Bloedvorming Complicaties Hémopathies - étiologie Therapieën Tumeurs - complications Tumoren Blood Diseases Hematologic Diseases etiology Neoplasms complications Tumors Hämoblastose Cytostatikum Koagulopathie Immunsuppression Arzneimittelnebenwirkung Krebs Medizin Tumoranämie Blutkrankheit Granulozytopenie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007167241&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000625446 |
| work_keys_str_mv | AT nimerstephend hematologiccomplicationsofcancer |